Tweetovi

Blokirali ste korisnika/cu @enricoferrero

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @enricoferrero

  1. Prikvačeni tweet
    13. pro 2019.

    Excited to see this work now published in ! We meta-analyse expression profiles of macrophages w/ different stimuli and build a classifier to label disease macrophages according to their activation status [1/5]

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    4. velj
    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    3. velj

    . we should move from the concept of “cell type” to “cell state”-single cell genomics allows us to see biology, dynamics & plasticity in ways not previously possible Interest in developing tech to see interactions & cell activity w/ single cell resolution

    Poništi
  4. proslijedio/la je Tweet
    3. velj

    : new protocol allows to preserve RNA+protein and can be combined with intracellular protein detection. Combine with CITE-seq and think about signaling, phosphoflow, transcription factors you will be able to measure! Will be a game-changer for multi-omics!

    Poništi
  5. proslijedio/la je Tweet
    26. sij

    Our pre-print on transfer learning for drug response prediction is out! We proposed a method based on adversarial learning and multi-task learning to adapt the gene expression of cell lines and patients and also to adapt different measures of the drug response between them.

    Poništi
  6. proslijedio/la je Tweet
    26. sij

    Our paper describing a gene expression signature of SLE identified across >7k samples and 40 independent studies has finally been published. Signature distinguishes SLE from other diseases (autoimmune and infectious) across tissues and cell types.

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    20. sij

    The eQTL data we use in Open Targets Genetics () are now available in the newly released eQTL Catalogue! All publicly available studies, processed through a uniform pipeline. Check it out 👇

    Poništi
  8. 16. sij

    Good review about network propagation and its applications to biomedical data

    Poništi
  9. 13. sij
    Prikaži ovu nit
    Poništi
  10. 13. sij

    Interested in working on multiomics data from thousands of patients in phase III clinical trials? Then join us as a Bioinformatics Scientist working across the Research and Development organizations of Novartis!

    Prikaži ovu nit
    Poništi
  11. 7. sij
    Poništi
  12. proslijedio/la je Tweet
    12. pro 2019.
    Poništi
  13. 13. pro 2019.

    Great collaboration with and many others at ! [5/5]

    Prikaži ovu nit
    Poništi
  14. 13. pro 2019.

    We can then apply this model to primary macrophages from different diseases and classify them according to their activation state and expression profile! [4/5]

    Prikaži ovu nit
    Poništi
  15. 13. pro 2019.

    Then we use the data to build an elastic net classifier of macrophage activation states using 97 genes [3/5]

    Prikaži ovu nit
    Poništi
  16. 13. pro 2019.

    We first collect gene expression profiles of macrophages differentiated and stimulated in vitro and perform a meta-analysis across 18 different studies [2/5]

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    4. pro 2019.

    This blog from illustrates that you need to dig into GWAS associations to identify believable gene assignments . Good lessons for our Open Targets Genetics Portal

    Poništi
  18. proslijedio/la je Tweet
    4. pro 2019.

    Really interesting work highlighting the importance of integrating multiple omics to assist patient stratification and identify potential drug targets for a polygenic trait

    Poništi
  19. proslijedio/la je Tweet

    the beginning of the year when we announced our 5 year partnership with Big Data Institute ! 📊 🤝 explains how the alliance could improve intervention & our understanding of diseases...

    Poništi
  20. 4. pro 2019.
    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·